Edition:
United Kingdom

Spectrum Pharmaceuticals Inc (SPPI.OQ)

SPPI.OQ on NASDAQ Stock Exchange Global Select Market

18.21USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$18.21
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
415,573
52-wk High
$21.95
52-wk Low
$4.21

Latest Key Developments (Source: Significant Developments)

Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update.Q3 non-GAAP loss per share $0.11.Q3 loss per share $0.22.Q3 revenue $36.4 million.  Full Article

Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer patients with Exon 20 insertion mutation in EGFR or HER2
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Spectrum Pharmaceuticals Inc :Spectrum Pharmaceuticals announces initiation of a multicenter phase 2 trial of poziotinib in non-small cell lung cancer (NSCLC) patients with Exon 20 insertion mutation in EGFR or HER2.  Full Article

Spectrum Pharma Q2 non-gaap loss per share $0.05
Tuesday, 9 Aug 2016 

Spectrum Pharmaceuticals Inc : Q2 loss per share $0.35 . Q2 earnings per share view $-0.29 -- Thomson Reuters I/B/E/S . Spectrum pharmaceuticals reports second quarter 2016 financial results and pipeline update . Q2 non-gaap loss per share $0.05 .Q2 revenue $33.9 million versus i/b/e/s view $30.9 million.  Full Article

Spectrum says unit Allos Therapeutics and Fresenius Kabi USA reach settlement to resolve patent litigation
Wednesday, 13 Jul 2016 

Spectrum Pharmaceuticals Inc : Spectrum says unit Allos Therapeutics and Fresenius Kabi USA entered into settlement agreement to resolve patent litigation relating to Folotyn . Details of settlement are confidential, parties will submit agreement to Federal Trade Commission and Department of Justice . Says Fresenius will be permitted to market a generic version of Folotyn In United States On November 15, 2022- Sec filing . Says parties will request that court enter an order, in which it will dismiss company's litigation against Fresenius .Says Fresenius was last remaining defendant in litigation, which accordingly is expected to conclude.  Full Article

Spectrum Pharmaceuticals' unit, Allos Therapeutics and Sandoz enter settlement agreement
Thursday, 9 Jun 2016 

Spectrum Pharmaceuticals Inc : On June 8, 2016, co's unit , Allos Therapeutics and Sandoz Inc entered into a settlement agreement . Spectrum Pharmaceuticals Inc says settlement agreement to resolve patent litigation relating to folotyn . Sandoz will be permitted to market generic version of folotyn in U.S on November 15, 2022 or earlier under certain circumstances . Details of settlement confidential, parties will submit agreement to ftc and department of justice . Spectrum Pharmaceuticals says parties will request that court enter an order, in which it will dismiss company's litigation against sandoz .Spectrum Pharmaceuticals Inc says company's litigation against one other generic filer continues.  Full Article

Spectrum Pharma says Dr Reddy's will be permitted to market generic version of Folotyn in US on Dec 1, 2022 or earlier
Tuesday, 31 May 2016 

Spectrum Pharmaceuticals : Co's unit, dr. Reddy's labs, ltd entered into settlement agreement to resolve their patent litigation relating to folotyn .dr. Reddy's will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain circumstances.  Full Article

Spectrum Pharma says unit, Teva enter settlement agreement
Wednesday, 25 May 2016 

Spectrum Pharmaceuticals Inc : Unit, teva pharmaceuticals usa, inc. Entered into settlement agreement to resolve patent litigation relating to Folotyn . Teva will be permitted to market generic version of folotyn in u.s. On december 1, 2022 or earlier under certain terms . Details of settlement are confidential, and parties will submit agreement to federal trade commission and doj .Parties will request that court enter an order, in which it will dismiss company's litigation against teva.  Full Article

Spectrum Pharmaceuticals says FDA grants orphan drug exclusivity to EVOMELA
Wednesday, 20 Apr 2016 

Spectrum Pharmaceuticals:Says FDA office of orphan products development has granted 7 years of Orphan Drug Exclusivity for EVOMELA for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.  Full Article

Spectrum Pharmaceuticals says FDA grants approval of EVOMELA for Injection
Tuesday, 15 Mar 2016 

Spectrum Pharmaceuticals:Says FDA grants approval of EVOMELA for Injection.Received FDA Approval for Two Indications : High-Dose Conditioning Treatment for Multiple Myeloma (MM) Patients Undergoing Autologous Stem Cell Transplantation (ASCT) , Palliative Treatment of Patients with MM Who Cannot Take Oral Therapy.Plans to Launch EVOMELA with Existing Sales Force in a Market Estimated at Approximately $100 Million.  Full Article

Spectrum Pharma says FDA's accepts NDA filing for eoquin
Friday, 19 Feb 2016 

Spectrum Pharmaceuticals Inc:Announces FDA's acceptance of nda filing for eoquin® (apaziquone for intravesical instillation).Says FDA also indicated that it plans to hold an advisory committee meeting regarding the nda.Says FDA has set a target action date under the prescription drug user fee act (pdufa) of December 11, 2016.  Full Article

BRIEF-Spectrum Pharmaceuticals reports Q3 non-GAAP loss per share of $0.11

* Spectrum Pharmaceuticals reports third quarter 2017 financial results and pipeline update